Today: September 17, 2024
Today: September 17, 2024

MBX Biosciences seeks up to $482.5 million valuation in US IPO

Illustration shows medicines
September 09, 2024
Reuters

(Reuters) - MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including obesity, said on Monday it was seeking a valuation of up to $482.5 million in its initial public offering in the United States.

Read More

Related

Business|Economy|Finance|News

Oil extends gains on US output concerns, expected drop in stockpiles

Oil prices extended gains on Tuesday as the market eyed U.S. output concerns in the aftermath of Hurricane Francine and expectations of lower U.S. crude stockpiles

Oil extends gains on US output concerns, expected drop in stockpiles
Asia|Business|Economy|Finance

Asia shares tentative; dollar, yields squashed on outsized Fed cut bets

Asian stocks wobbled on Tuesday while the dollar and U.S.

Asia shares tentative; dollar, yields squashed on outsized Fed cut bets
Business|Travel|World

This airport landing is so challenging only 50 pilots are qualified do it

This airport landing is so challenging only 50 pilots are qualified do it

This airport landing is so challenging only 50 pilots are qualified do it
Share This

Popular

Asia|Business|Finance|Stock Markets

Midea Group shares rise 9.5% in Hong Kong after $4 billion listing

Midea Group shares rise 9.5% in Hong Kong after $4 billion listing
Business|Finance|Technology

Trump offers little detail at crypto business unveiling

Trump offers little detail at crypto business unveiling
Asia|Business|Economy|News

Japan finance minister says Seven & i's new 'core' tag doesn't raise bar for buyout

Japan finance minister says Seven & i's new 'core' tag doesn't raise bar for buyout
Business|Economy|Environment

Brazil confirms potential $18 billion deal with miners involved in deadly dam disaster

Brazil confirms potential $18 billion deal with miners involved in deadly dam disaster